DDInter899 DDInter1032
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved
Lefamulin is a pleuromutilin antibiotic used for the treatment of bacterial community-acquired pneumonia. A pleuromotilin is a more recently developed type of antibiotic that is derived from the fungus, Pleurotus mutilus. Lefamulin is available in intravenous and oral preparations and was granted FDA approval in August 2019. This drug is the first semi-synthetic pleuromutilin that has been designed for systemic administration. Lefamulin features a novel mechanism of action that shows benefit against resistant bacteria that cause pneumonia. The chemical structure of lefamulin contains a tricyclic mutilin core that is necessary for some of its antimicrobial activity.
Lefamulin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Lefamulin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Larotrectinib
Lefamulin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Octreotide
Lefamulin {u} may lead to a major life threatening interaction when taken with {v} Vandetanib
Lefamulin {u} may lead to a major life threatening interaction when taken with {v} Macimorelin
Lefamulin may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Lefamulin may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Lefamulin may cause a moderate interaction that could exacerbate diseases when taken with Octreotide
Lefamulin may lead to a major life threatening interaction when taken with Vandetanib
Lefamulin may lead to a major life threatening interaction when taken with Macimorelin